The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

or it had a different mechanism of action. “There’s a lot of hype and excitement around GLP-1 and like medications,” Youssef. “And the thing I want to see is long-term safety data.

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... effect of GLP1-RA on kidney function in patients with moderate to ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in addiction treatment as they have been in reducing obesity.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide ... "More research is needed to understand the mechanisms of action of these medications in AUD; nonetheless, the work ...

[1] In the presence of elevated glucose concentrations, GLP-1 and GIP ... beyond its proteolytic action, including T-cell activation and proliferation. Although the mechanism of action may ...

1 Hydroxychloroquine ... efficacy in the treatment of RA, SLE and other rheumatic diseases. Besides providing a better understanding of the mechanisms of action of antimalarial agents in rheumatic ...